Survival questions delay bemarituzumab
Ocular toxicities could be the reason.
Zymeworks becomes the latest mesothelin dropout
The group cans ZW171 after “on-target, off-tumour toxicity”.
Ivonescimab back in tune
China's Harmoni-A trial hits on overall survival, but hopes for a global phase 3 seem optimistic.
World Lung 2025 preview – best of the rest
Posters and mini-orals include another VEGF bispecific.
Pfizer’s Global Blood buy fails to Thrive
Inclacumab fails, and osivelotor is on hold.
